Cryogenic Solutions Inc. (CYGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: celeryroot.com who wrote (3268)	8/21/1998 11:01:00 AM
From: Graham Marshman	Read Replies (2) of 4028

Bureaucracy never changes as fast as we'd like, but it is gratifying to see some positive progress and it does keep moving in the right direction. There also significant depths in this subject when it comes to stocks. They do not appreciate on a big bang theory, they do not stagnate until final approval. Abella, when he was at Westergaard had a valuation model that was excellent in understanding fair value of biomed stocks. Taken off when he left, but significant factors are: 1) A potential market cap contribution for each application set according to market size and first year penetration. 2) Actual market cap contribution calculated by using a factor based on status. Preclin was a flat $5M. Phase I was 30% of potential, phase II 40% etc. up to 80% with an NDA 3) Add market cap from patents 4) Calculate management factor multiplier based on 5 year revenue/defecit. The point here is, there are very significant gains to be made in market cap in early stages. I also believe the reductions that both already have been achieved and can be expected from FDA reform are more positive to market value for biomeds than have currently been appreciated by the market. Graham

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next